# Omacetaxine for Consolidation and Maintenance

> **NCT01873495** · PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 7 (actual)

## Conditions studied

- Acute Myelogenous Leukemia (AML)

## Interventions

- **DRUG:** Omacetaxine

## Key facts

- **NCT ID:** NCT01873495
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873495, "Omacetaxine for Consolidation and Maintenance". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01873495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*